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OBJECTIVE
Increases in serum calcitonin, a tumor marker for medullary thyroid carcinoma
(MTC), have been associated with glucagon-like peptide 1 receptor agonist use in
some preclinical studies. We report calcitonin changes in exenatide-treated and
placebo-administered participants and MTC incidence in the EXenatide Study of
Cardiovascular Event Lowering (EXSCEL) and consider the impact of within-trial
calcitonin monitoring.
RESEARCH DESIGN AND METHODS
EXSCEL participants were randomized 1:1 to once-weekly exenatide 2 mg or
placebo. Serum calcitonin was measured at baseline (with trial medication
discontinued if >40 ng/L) and annually thereafter (with trial medication discon-
tinued if ‡50 ng/L). Median calcitonin concentrations were calculated at each time
point, and thyroid malignancies were collected prospectively. Data regarding
follow-up after an elevated calcitonin were collected retrospectively.
RESULTS
At baseline, 52 (30 exenatide and 22 placebo) participants had calcitonin >40 ng/L,
and during follow-up an additional 23 participants (15 exenatide and 8 placebo) had
calcitonin ‡50 ng/L in the intention-to-treat population. Median calcitonin con-
centrations were similar between treatment groups at baseline with no increase
over time. Confirmed MTC occurred in three participants (2 exenatide and 1
placebo), all ofwhomhad significantly elevatedbaseline calcitonin values (413, 422,
and 655 ng/L).
CONCLUSIONS
During a median 3.2 years’ follow-up, no change in serum calcitonin was seen with
exenatide therapy. The three confirmed cases of MTC all occurred in participants
with markedly elevated baseline calcitonin levels, measured prior to trial med-
ication administration. Regular calcitonin monitoring identified no additional cases
of MTC, suggesting no benefit of routine calcitonin monitoring during exenatide
treatment.
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Glucagon-like peptide 1 receptor ago-
nists (GLP-1 RAs) are effective glucose-
lowering treatments for type 2 diabetes
that present a low risk of hypoglycemia, a
potential for weight loss, and, for some
agents, reduced risk of major adverse
cardiovascular events (1,2). Preclinical
rodent studies of the GLP-1 RAs liraglu-
tide and exenatide demonstrated a dose-
dependent increase in serum calcitonin
levels, a biomarker for thyroid C-cell dis-
eases such as medullary thyroid car-
cinoma (MTC), raising concern about
potential off-target effects on the thyroid
gland (3). Liraglutide use was associated
with development of C-cell carcinomas in
rats (already predisposed to spontaneous
development of C-cell lesions with age)
and in female mice exposed to very high
doses (;45 times that used in human
studies) (4,5). In contrast, preclinical stud-
ies with exenatide demonstrated in-
creased incidence of C-cell adenomas
(not carcinomas) in female rats at expo-
sures 130 times the clinical dose and no
C-cell pathology in mice (6). Neither lir-
aglutide nor exenatide was associated
with C-cell pathology in primates (3,6).
Because of these species differences in
C-cell response, the relevance to humans
of the preclinical carcinogenicity data
was unclear at the time that large-scale
cardiovascular outcomes trials (CVOTs)
withGLP-1RAswere initiated.As a result,
regulatory agencies mandated regular
serum calcitonin concentration monitor-
ing during GLP-1 RA CVOTs for safety
reasons to assess the potential impact on
calcitonin levels over time and to eval-
uate risks for C-cell hyperplasia or ma-
lignancy. We report the results for the
calcitonin data collected during the EX-
enatide Study of Cardiovascular Event
Lowering (EXSCEL), as well as the inci-
dence of MTC during the trial, and the
impact of routine serum calcitonin con-
centration monitoring in patients with
type2diabetes treatedwithonce-weekly
exenatide 2 mg.
RESEARCH DESIGN AND METHODS
Trial Design
The design and primary results of EXSCEL
havepreviouslybeendescribed (7,8). The
trial was conducted jointly by the Duke
Clinical Research Institute and the Uni-
versity of Oxford Diabetes Trials Unit in
an academic collaborationwith the spon-
sor, Amylin Pharmaceuticals, a wholly
owned subsidiary of AstraZeneca. The
protocol was approved by the ethics
committee at each participating site,
and all participants provided written in-
formed consent for trial participation.
Briefly, 14,752 adults with type 2 diabe-
tes who either had experienced a prior
cardiovascular event (10,782 [73.1%]) or
were at any level of risk for a primary
cardiovascular event (3,970 [26.9%])
were randomized 1:1 to receive once-
weekly exenatide 2 mg or placebo, in
addition to usual care, and followed up
over a median of 3.2 years. The trial
inclusion and exclusion criteria are listed
in Supplementary Data. The primary out-
comewas defined as the first occurrence
of a three-component major adverse car-
diovascular event outcome (death from
cardiovascular causes, nonfatal myocar-
dial infarction, or nonfatal stroke) in
a time-to-event analysis. Protocol-specified
exclusion criteria related to calcitonin and
thyroid tumors included a baseline serum
calcitonin concentration .40 ng/L or
a personal or family history of MTC or
multiple endocrine neoplasia type 2. Ran-
domization and administration of trial
medicationwerepermittedprior toknow-
ing the baseline calcitonin value. If an
elevated baseline calcitonin value (.40
ng/L) was discovered, trial medication was
discontinued immediately, with the par-
ticipant continuing to be followed until
trial cessation. Additionally, the develop-
ment of a serum calcitonin concentration
$50 ng/L during postrandomization ne-
cessitated immediate discontinuation of
trial medication and notification of the
participant’s usual care provider, with the




Serum calcitonin concentrations were
measured at baseline, annually through-
out follow-up, and at the final study
follow-up visit. Samples, which were
not required to be taken while fasting,
were analyzed at local laboratories until
July 2010, after which they were all
analyzed at a central laboratory (Quin-
tiles Laboratories Ltd.) using a Siemens
Healthcare IMMULITE 2000 assay. The
within-run coefficient of variation for the
IMMULITE 2000 assay was 2.8–15.7%
with acceptance criteria of #10%. The
earliest recorded elevated calcitonin was
collected in September 2010. All assay
results were included in the final analysis.
Investigators and participants were
blinded to serum calcitonin concentra-
tion values unless a protocol-defined
elevation was detected. If a serum cal-
citonin concentration was elevated ei-
ther at baseline (.40 ng/L) or during
follow-up ($ 50 ng/L), site investigators
were given the numeric result, directed
to discontinue study medication imme-
diately, and asked to alert the partici-
pant’s usual care provider to consider
additional follow-up investigations. Dur-
ing the trial, unblinded serum calcitonin
concentrations were reviewed at regular
intervals by the Data and Safety Moni-
toring Board, which included a thyroid
cancer specialist (R.F.G.).
Data on all malignancies, including
MTC, were collected prospectively
throughout the trial, and allmalignancies
were adjudicated using prespecified cri-
teria (Supplementary Data) by an indepen-
dent committee, blinded to treatment
assignment.
Impact of Routine Serum Calcitonin
Concentration Monitoring
Site investigatorswere asked to complete
an ancillary calcitonin case report form
(Supplementary Data) for all participants
who had an elevated serum calcitonin
concentration at baseline (.40 ng/L) or
during follow-up ($50 ng/L) retrospec-
tively between July 2016 and May 2017.
This formcapturedadditional information
about the participants such as referral to
specialists, investigations, andprocedures
performed. Repeat calcitonin measure-
ments were performed outside of the
trial following referral to usual care pro-
viders or thyroid specialists. Whether or
not a repeat measurement was per-
formed in the local health care setting
was captured on the ancillary calcitonin
case report form, but the results of any
such measurements were not collected
robustly, as it was not mandatory for site
investigators to record them.
Statistical Analysis
Baseline characteristicswere summarized
for participants with and without a ser-
um calcitonin concentration elevation at
any time during the trial as median (25th
percentile [Q1], 75th percentile [Q3])
for continuous variables and number
(percentages) for categorical variables.
Median serum calcitonin concentrations
for treatment groups were calculated at
baseline and then yearly for the overall
population and for male and female
subgroups.Median serumcalcitonin con-
centrations were also calculated for
values above the upper 95% range of
the assay used (8.4 ng/L for males and
5.0 ng/L for females) at any time during
the trial.
Follow-up data for patients with a
protocol-specified calcitonin elevation
were summarized using descriptive
statistics. Costs were estimated for all
follow-up activities using Medicare reim-
bursement rates for procedures, physician
visits, and clinical diagnostic laboratory
fees derived from Current Procedural
Terminology (CPT) or Diagnosis Related
Group (DRG) codes assigned to each fol-
low-up activity (Supplementary Table 1).
RESULTS
Safety Outcomes
A total of 12,831 participants had a
baseline and at least one postbaseline
serum calcitonin concentration mea-
sured and were included in this analysis.
In the baseline intention-to-treat popu-
lation, 52 (30 exenatide and 22 placebo)
participants had a serum calcitonin
concentration .40 ng/L, and during
follow-up an additional 23 participants
(15exenatide and8placebo) hada serum
calcitonin concentration $50 ng/L. Me-
dian baseline serum calcitonin concen-
tration was 1.7 ng/L (Q1 1.7, Q3 4.3) in
the exenatide group and 1.7 ng/L (1.7,
4.2) in the placebo group, with no dif-
ference between male and female sub-
groups in each treatment arm and no
changes over time (Fig. 1); median differ-
ences between baseline and 3 years were
0.0 ng/L (20.4, 0.0) and 0.0 ng/L (20.5,
0.0) in the exenatide and placebo groups,
respectively.
Figure 1—Median serum calcitonin concentrations over time by male and female treatment groups in the intention-to-treat population.




















































*Sample drawn prior to any trial medication administration.
Participants with a calcitonin elevation
at any time (n = 75) had a median age of
66.0 years (Q1 59.0, Q3 71.0), were
predominantly male (78.7%), and were
most likely to be from either North
America (45.3%) or Europe (42.7%)
(Supplementary Table 2). There were
2,502 patients (17.0%: 2,102 male and
400 female) with at least one serum
calcitonin concentration above the 95%
range of the assay used (.8.4 ng/L for
males and .5.0 ng/L for females), with
median serum calcitonin concentrations
of 12.9 ng/L (10.2, 18.3) for males and 7.8
ng/L (6.2, 12.4) for females in these
cohorts. Among thosepatientswithapro-
tocol-defined elevation in calcitonin, ei-
ther at baseline or during follow-up, the
median (IQR) and range were 58.1 ng/L
(50.7, 74.8) and 40.4–1003.0, respec-
tively.
A confirmed MTC occurred in three
participants (2 exenatide and 1 placebo),
all of whom had markedly elevated se-
rum calcitonin concentrations at base-
line: 413, 422, and 655 ng/L (Table 1).
Impact of Routine Serum Calcitonin
Concentration Monitoring
Follow-up data were available for 70 of
the 75 participants who had an elevated
serum calcitonin concentration. Reasons
for form noncompletion were site clo-
sure (n = 3) or unknown (n = 2). The
majority of participants with elevated
calcitonin and follow-up data available
were referred to their usual careprovider
(46 of 70 [66%]) or a thyroid specialist
(41 of 70 [59%]). Just over half (37 of
70 [53%]) had at least one diagnostic test
or procedure performed, with the most
common being a thyroid ultrasound
(32 of 37 [87%]), fine needle aspiration
(9 of 37 [24%]), or surgical intervention
(4 of 37 [11%]) (Table 2). Of participants
who had a thyroid ultrasound, 75% (24 of
32) had benign findings, most commonly
clinically insignificant nodules (,1 cm) or
goiter, and required no further clinical
evaluation in the opinion of the treating
medical team. Nine participants under-
went a fine needle aspiration procedure:
five had benign or nondiagnostic findings
requiring no further evaluation in the
opinionof the treatingmedical team, and
four had findings requiring surgical in-
tervention. Of the four participants re-
quiring surgical intervention, three were
those participants with confirmed MTC
who underwent a total thyroidectomy,
whileoneparticipantunderwentapartial
thyroidectomy for a 4.5-cm left upper
lobe solid, hypoechoic benign nodule
containing microcalcifications; the final
pathology showed a colloid nodule. Es-
timated overall total costs for follow-up
activities undertaken in local healthcare
systems following an elevated serum
calcitonin concentration are shown in
Table 2. Just under half (49%) of the
total cost to local health care systemswas
attributable to the follow-up received by
the three participants with MTC.
CONCLUSIONS
In EXSCEL, treatment with once-weekly
exenatide2mghadno impact (compared
with placebo) on serum calcitonin concen-
trations over a median 3.2-year follow-up
Table 2—Follow-up received by participants with elevated serum calcitonin concentrations at any time during EXSCEL by
clinical outcome, with associated estimated costs to local health care systems
Calcitonin elevation and
benign outcome (n = 66)
Calcitonin elevation and
MTC outcome (n = 3)
Calcitonin elevation and













Participants with repeat serum calcitonin
measurementsperformed in local health care
systems 40 3 1
Total no. of repeat serum calcitonin sample
measurements in local health care systems 90 2,977.20 5 165.40 1 33.08
Participants referred to usual care provider by site
investigator‡ 42 3,174.36 3 226.74 1 75.58
Participants referred to thyroid specialist by site
investigator or usual care provider‡ 37 6,289.26 3 509.94 1 169.98
Participants with any diagnostic test/procedure
performed in local health care system 33 3 1
Thyroid ultrasound 28 3,042.76 3 326.01 1 108.67
Fine needle aspiration 5 2,021.20 3 1,212.72 1 404.24
Surgical intervention 0 3 1
Partial thyroidectomy 0 d 0 d 1 6,677.13
Total thyroidectomy without lymph node
dissection 0 d 1 6,897.76 0 d
Total thyroidectomy with lymph node
dissection 0 d 2 14,626.52 0 d
Pentagastrin stimulation test 1 231.56 0 d 0 d
Genetic testing for germline RET mutations 1 282.88 0 d 0 d
Estimated total cost by clinical outcome (USD) 18,019.22 23,965.09 7,468.68
Estimated total cost (USD) 49,452.99
Mean cost per participant (USD) 706.50
*“Other” outcome refers to one participant who underwent a partial thyroidectomy for a 4.5-cm hypoechoic benign colloid nodule containing
microcalcifications. †Cost calculated bymultiplying total number byMedicare reimbursement fee amounts according to CPTorDRG coding (list of CPT/
DRG codes and associated fee schedules are shown in Supplementary Table 1). ‡Participants assumed to have had a single appointment if referred to
usual care provider or a thyroid specialist.
period. All three confirmed cases of MTC
in EXSCEL occurred in participants who
had markedly elevated serum calcitonin
concentrations at baseline, prior to any
trial medication administration.
Our findings are consistent with those
from a similar post hoc analysis performed
in the Liraglutide Effect and Action in
Diabetes: Evaluation of Cardiovascular
Outcome Results (LEADER) trial (9). In
LEADER, no increase in calcitonin concen-
tration was observed in participants ran-
domized to liraglutide versus placebo at
36months, and therewere noepisodes of
MTC in liraglutide-treated participants.
Determining appropriate protocol-
specified calcitonin thresholds for study
drug discontinuation in EXSCEL was not
straightforward. In routine clinical prac-
tice, calcitonin levels are effective tumor
markers to monitor treatment and pro-
gression but are not recommended as
screening or diagnostic tools, especially
in unselected populations (10).Markedly
elevated serum calcitonin concentra-
tions (.100 ng/L) have a high specificity
for MTC (10), but there is no consen-
sus defining a clinically meaningful ele-
vated concentration below this value.
The 2009 American Thyroid Association
(ATA) guidelinesdthemost recent at the
time of EXSCEL protocol developmentd
did not recommend for or against the
routine measurement of serum calcito-
nin in patients with thyroid nodules
but did recommend that an unstimulated
calcitonin concentration .100 ng/L was
suggestive of MTC in the presence of
nodules (10). In comparison, the most
recent 2015 ATA guidelines advise that a
calcitonin concentration .50–100 ng/L
should prompt further investigation for
MTC in patients with thyroid nodules.
The European perspective differs sub-
stantially, with the European Thyroid
Association recommending that routine
measurement of calcitonin be included in
the evaluation of patients with a thyroid
nodule or multinodular goiter (11). Both
the ATA and European Thyroid Associa-
tion make no recommendations for cal-
citonin screening in thewider population
(12). In the absence of clear data re-
garding the positive predictive value of
modestly elevated calcitonin values for
MTC in a population unselected for thy-
roid disease and in consultation with
thyroid disease experts, a baseline cal-
citonin threshold of .40 ng/L was cho-
sen for EXSCEL (13). A within-trial
threshold for study drug discontinuation
of $50 ng/L was chosen to allow for a
variation of ;20% in assay measure-
ments.
Protocol-mandated routine monitor-
ing of serum calcitonin concentrations in
EXSCEL identified a total of 75 partici-
pants with an elevated calcitonin con-
centration and three participants with
previously undiagnosed MTC at an esti-
mated cost of;8 million USD to the trial
and ;49,500 USD to local health care
systems. Although these three partici-
pants may have benefitted from having
their serum calcitonin concentrations
measured at the beginning of the trial,
the detection and treatment of their
cancers was not associated with the
use of exenatide therapy. Importantly,
no further cases of MTC were identified
during the trial follow-up period. In con-
trast, the imposed calcitonin monitoring
program resulted in multiple unneces-
sary investigations and procedures in
those with sporadically or modestly el-
evated calcitonin levels. Other important
unmeasured costs to participants related
to receiving an “abnormal” test result are
more difficult to quantify and include
worry and anxiety over a potential cancer
diagnosis and potential loss of produc-
tivity because of time away fromwork to
attend follow-up appointments.
Limitations of this analysis include the
relatively short median follow-up of 3.2
years in EXSCEL, which may not have
been long enough to detect indolent MTC
development (14); the retrospective na-
ture of elevated calcitonin follow-up data
collection via ancillary case report forms,
which may have been subject to recall
bias; and lack of follow-up data for five
participants who had an elevated serum
calcitonin concentration. Furthermore,
the method of follow-up of abnormal
calcitonin values was not prescribed by
the protocol, instead deferring to local
referral and practice patterns. Conse-
quently, there was no predefined and
unique strategy for follow-up and man-
agement of those excluded from the
study because of calcitonin elevations.
While individual calcitonin values can be
impacted by factors such as age, smoking
status, and renal function, the impact on
absolute calcitonin values is small. No
adjustments were made for baseline
covariates, as these were equally distrib-
uted between treatment groups (8) and
therefore unlikely to have confounded
our findings of no impact of exenatide
therapy on calcitonin values during fol-
low-up. Strengths include analysis of a
data set from a large population in a
randomized controlled trial setting and
the robust assessment of all reported
thyroid malignancies by an independent
blinded committee using prespecified
adjudication criteria.
In summary, this EXSCEL post hoc anal-
ysis shows no evidence that treatment
with once-weekly exenatide 2 mg in-
creases serum calcitonin concentrations
or increases risk forMTC inhumansduring
;3 years’ follow-up. These data, in con-
cert with those from LEADER, provide
;83,000 patient-years’ follow-up and
should provide reassurance that GLP-1
RA therapy does not increase short-
term risk for MTC. Calcitonin screening
is not recommended in clinical care except
in the evaluation of nodular thyroid
disease, if a family history of MTC exists,
or if multiple endocrine neoplasia type 2
is suspected. Given the trial-related and
societal costs of these screening pro-
grams, it may be prudent to revisit
regulatory requirements for calcitonin
screening in future GLP-1 RA trials unless
they are likely to contribute novel insights
through longer-term follow-up or via en-
rollment of relevant patient populations.
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